Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Oncology·MeSH: Squamous Cell Carcinoma of Head and Neck
Prevalence
14.0 / 100K
Incidence
6.0 / 100K/yr
3 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| pds0101 | PDS Biotechnology Corp (PDSB) |
Phase 2(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma?
BioSniper tracks 3 drugs in development for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma across 2 companies.
How many clinical trials target Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma?
There are 1 clinical trial targeting Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma tracked by BioSniper.
What is the prevalence of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma?
The estimated prevalence of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma is approximately 14.0 per 100,000 population.
Deep-dive into Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis